READERS may wonder what has happened to our regular analysis of MHRA Yellow Card Covid vaccine adverse events data since our last report on April 21. My apologies are due. My forgetfulness – not MHRA negligence for once – is the reason. In fact there have been three Yellow Card releases since then, one up to May 31, a second to July 26 and the most recent at the end of August, which Jenny Brown is analysing for us right now.
She provided us with a full breakdown of the May 31 data last June, including the various categories of severe reactions, and a summary of the July 26 release a few weeks ago.
The headlines drawn from these are shocking beyond belief.
· The 1 in 191 reports associated with a fatality (397 of which are of unknown age) reported by the end of May had risen to 1 in 188 by the end of July – in sum 2,564 equalling 0.5 per cent of all reports (and an increase of 45 fatalities in just those eight weeks);
· 1,696 more people impacted by adverse event since the previous April report;
· By May 31, 480,658 people in total impacted;
· The 357,931 reports acknowledged to be serious by the end of May (9.6 per cent of which are of people of ‘unknown’ age) had risen to 358,559 by the end of July;
· The total number of reported reactions now well above the one and half million mark;
· 32,023 acute cardiac disorders reported (May 31);
· And 58,869 reproductive and breast disorders (May 31);
· ‘Greater than’ 16 under-19 fatalities reported on May 31, by end of July had risen to ‘greater than’ 17;
· The 43 ’20-29-year-old’ fatalities by end of July had become ‘greater than’ 45.
Yet the government recklessly continues to push the booster on to all age groups.
This is the full MHRA May 31 breakdown:
Yellow Card Adverse Event Reports
176,914 (Pfizer-mono) + 4,687 (Pfizer-bivalent) + 248,194 (AZ) + 42,941 (Moderna-mono) + 5,345 (Moderna-bivalent) + 75 (Novavax) + 2,502 (Unknown brand) = 480,658 people impacted (1,696 people in nine weeks)
Reports classified as SERIOUS* by MHRA = 74.4 per cent of all reports
125,220 (Pfizer-mono) + 3,609 (Pfizer-bivalent) + 192,287 (AZ) + 31,057 (Moderna-mono) + 3,899 (Moderna-bivalent) + 54 (Novavax) + 1,805 (Unknown) = 357,931
Over 46,158 of the above serious reports are of ‘unknown age’ = 9.6 per cent of all reports
Reports classified as non-serious by MHRA = 25.1 per cent
50,812 (Pfizer-mono) + 1,039 (Pfizer-bivalent) + 54,521 (AZ) + 11,794 (Moderna-mono) + 1,402 (Moderna-bivalent) + 21 (Novavax) + 619 (Unknown) = 120,208
Overall 1-in-112 people injected experiences a Yellow Card Adverse Event (assuming one person submits only one report)
1-in-150 people injected experiences an adverse event classified as SERIOUS*
1-in-187 reports are associated with a fatality, which may be less than 10% of actual figures according to MHRA
Fatal
882 (Pfizer-mono) + 39 (Pfizer-bivalent) + 1,386 (AZ) + 90 (Moderna-mono) + 44 (Moderna-bivalent) + 78 (Unknown) = 2,519 = 0.52 per cent of all reports (increase of 46 reports with fatal outcome in nine weeks)
Over 397 of the above fatalities are of ‘unknown age’ = 15.8 per cent of all fatalities, and 143 are of ‘unknown sex’ = 5.7 per cent of all fatalities
Reactions
510,540 (Pfizer-mono) + 12,468 (Pfizer-bivalent) + 881,010 (AZ) + 141,059 (Moderna-mono) + 14,582 (Moderna-bivalent) + 237 (Novavax) + 7,749 (Unknown) = 1,567,645
Reaction types (more than one reaction may be reported in one report – partial listing)
Blood & Lymphatic Disorders – 17,436 (Pfizer-mono) + 433 (Pfizer-bivalent) + 8,000 (AZ) + 2,679 (Moderna-mono) + 224 (Moderna-bivalent) + <5 (Novavax) + 80 (Unknown brand) = 28,852
Anaphylaxis – 681 (Pfizer-mono) + 17 (Pfizer-bivalent) + 886 (AZ) + 100 (Moderna-mono) + <5 (Moderna-bivalent) + 7 (Novavax) + 5 (Unknown brand) = 1,696
Acute Cardiac Disorders – 14,428 (Pfizer-mono) + 751 (Pfizer-bivalent) + 12,157 (AZ) + 3,870 (Moderna-mono) + 574 (Moderna-bivalent) + 14 (Novavax) + 229 (Unknown) = 32,023
Eye Disorders – 8,497 (Pfizer-mono) + 192 (Pfizer-bivalent) + 15,304 (AZ) + 1,787 (Moderna-mono) + 229 (Moderna-bivalent) + <5 (Novavax) + 136 (Unknown) = 26,145
· Of which Blindness – 187 (Pfizer-mono) + <5 (Pfizer-bivalent) + 363 (AZ) + 47 (Moderna-mono) + <5 (Moderna-bivalent) + 7 (Unknown) = 604
Infections & Infestations – 13,648 (Pfizer-mono) + 501 (Pfizer-bivalent) + 21,275 (AZ) + 2,931 (Moderna-mono) + 438 (Moderna-bivalent) + 10 (Novavax) + 333 (Unknown) = 39,136
· Of which Herpes – 2,336 (Pfizer-mono) + 50 (Pfizer-bivalent) + 2,470 (AZ) + 307 (Moderna-mono) + 68 (Moderna-bivalent) + <5 (Novavax) + 34 (Unknown) = 5,535
Gastrointestinal Disorders – 43,809 (Pfizer-mono) + 1,031 (Pfizer-bivalent) + 81,714 (AZ) + 12,498 (Moderna-mono) + 1,595 (Moderna-bivalent) + 19 (Novavax) + 577 (Unknown) = 141,243
Nervous System Disorders – 84,950 (Pfizer-mono) + 1,920 (Pfizer-bivalent) + 186,047 (AZ) + 23,145 (Moderna-mono) + 2,456 (Moderna-bivalent) + 29 (Novavax) + 1,299 (Unknown) = 299,846
· Of which Seizures – 1,348 (Pfizer-mono) + 27 (Pfizer-bivalent) + 2,321 (AZ) + 336 (Moderna-mono) + 39 (Moderna-bivalent) + <5 (Novavax) + 46 (Unknown) = 4,117
· Paralysis & Paresis – 557 (Pfizer-mono) + 19 (Pfizer-bivalent) + 930 (AZ) + 149 (Moderna-mono) + 13 (Moderna-bivalent) + 16 (Unknown) = 1,684
· Tremor – 2,315 (Pfizer-mono) + 67 (Pfizer-bivalent) + 10,037 (AZ) + 839 (Moderna-mono) + 109 (Moderna-bivalent) + 67 (Unknown) = 13,434
Tinnitus & Vertigo – 4440 (Pfizer-mono) + 139 (Pfizer-bivalent) + 7,025 (AZ) + 847 (Moderna-mono) + 129 (Moderna-bivalent) + <5 (Novavax) + 74 (Unknown) = 12,654
Psychiatric Disorders – 10,795 (Pfizer-mono) + 272 (Pfizer-bivalent) + 18,909 (AZ) + 2,848 (Moderna-mono) + 269 (Moderna-bivalent) + <5 (Novavax) + 191 (Unknown) = 33,284
Strokes & CNS Haemorrhages – 837 (Pfizer-mono) + 36 (Pfizer-bivalent) + 2,363 (AZ) + 86 (Moderna-mono) + 32 (Moderna-bivalent) + <5 (Novavax) + 39 (Unknown) = 3,393
Bells’ Palsy & Facial Paralysis – 1,188 (Pfizer-mono) + 23 (Pfizer-bivalent) + 1037 (AZ) + 181 (Moderna-mono) + 31 (Moderna-bivalent) + 7 (Unknown) = 2,467
Respiratory Disorders – 22,966 (Pfizer-mono) + 757 (Pfizer-bivalent) + 30,368 (AZ) + 5,034 (Moderna-mono) + 805 (Moderna-bivalent) + 12 (Novavax) + 348 (Unknown) = 60,290
Reproductive/Breast Disorders – 31,848 (Pfizer-mono) + 172 (Pfizer-bivalent) + 21,064 (AZ) + 5,385 (Moderna-mono) + 103 (Moderna-bivalent) + <5 (Novavax) + 297 (Unknown) = 58,869
Skin Disorders – 35,786 (Pfizer-mono) + 833 (Pfizer-bivalent) + 54,226 (AZ) + 14,332 (Moderna-mono) + 992 (Moderna-bivalent) + 17 (Novavax) + 538 (Unknown) = 106,724
CHILDREN & YOUNG PEOPLE SPECIAL REPORT
Last available data set for under-18s in Nov 2022
· 4,213,500 children (1st doses) – majority Pfizer
· 2,910,500 (2nd doses) – majority Pfizer
· 485,900 boosters
Yellow Card Adverse Events Reported – Below combined 0-19yrs – many categories retracted (^) due to fewer than five reports ‘in line with MHRA duty of confidentiality to patients and reporters’.
0-19-yr-old reports classified as SERIOUS* by MHRA = 71.5%
4,668 (Pfizer-mono) + 38 (Pfizer-bivalent) + 1,462 (AZ) + 518 (Moderna-mono) + 7 (Moderna-bivalent) + 36 (Unknown) = 6,729
0-19-yr-old reports classified as FATAL by MHRA
>11 (Pfizer-mono) + <5 (Pfizer-bivalent) + <5 (AZ) + <5 (Moderna-mono) + <5 (Moderna-bivalent) + <5 (Unknown brand) = greater than 16
20-29-yr-old reports classified as SERIOUS* by MHRA = 73.4 per cent
20,012 (Pfizer-mono) + 121 (Pfizer-bivalent) + 14,554 (AZ) + 4,982 (Moderna-mono) + 133 (Moderna-bivalent) + < 5 (Novavax) + 96 (Unknown) = 39,898
20-29-yr-old reports classified as FATAL by MHRA
15 (Pfizer-mono) + <5 (Pfizer-bivalent) + 28 (AZ) + zero (Moderna-mono) + zero (Moderna-bivalent) + zero (Novavax) + zero (Unknown brand) = greater than 43
*MHRA definition of ‘serious’ – patient died, life threatening, hospitalisation, congenital abnormality, persistent or significant disability or capacity, deemed medically significant by MHRA medical dictionary or reporter
For full reports please see here.
* * *
Here is Jenny’s reporting summary to July 26 2023
(New interactive format data)
Adult & Child – Primary, Third Dose & Boosters (mono/bivalent)
Government data (archived) up to September 2022 showed53.8million people had received a 1st dose UK-wide.
By week ending July 2, 2023, 71.1% (3,856,204 out of 5,423,074) people aged over 75 years old and 41.2% (915,421 out of 2,223,120) people aged 5 years and over who are immunosuppressed (England only) had a Spring 2023 booster since April 3, 2023 UKHSA National Flu & Covid-19 Surveillance Report – week 35
Yellow Card Adverse Event Reports
177,207 (Pfizer-mono) + 4,977 (Pfizer-bivalent) + 248,394 (AZ) + 42,988 (Moderna-mono) + 5,435 (Moderna-bivalent) + 78 (Novavax) + 2,579 (Unknown brand) = 481,658 people impacted (increase of 1000 in eight weeks)
Reports classified as SERIOUS* by MHRA = 74.5% of all reports
125,461 (Pfizer-mono) + 3,846 (Pfizer-bivalent) + 192,458 (AZ) + 31,100 (Moderna-mono) + 3,967 (Moderna-bivalent) + 58 (Novavax) + 1,869 (Unknown) = 358,759
Over 46,282 of the above serious reports are of ‘unknown age’ = 12.9% of all serious reports
Reports classified as Non-SERIOUS by MHRA = 25.0%
50,853 (Pfizer-mono) + 1,090 (Pfizer-bivalent) + 54,527 (AZ) + 11,797 (Moderna-mono) + 1,421 (Moderna-bivalent) + 20 (Novavax) + 627 (Unknown) = 120,335
Overall 1-in-112 people injected experiences a Yellow Card Adverse Event (assuming one person submits only one report)
1-in-150 people injected experiences an adverse event classified as SERIOUS*
1-in-187 reports are associated with a fatality, which may be less than 10% of actual figures according to MHRA
511,455 (Pfizer-mono) + 13,271 (Pfizer-bivalent) + 881,283 (AZ) + 141,225 (Moderna-mono) + 14,862 (Moderna-bivalent) + 243 (Novavax) + 7,950 (Unknown) = 1,570,289
Fatal
893 (Pfizer-mono) + 41 (Pfizer-bivalent) + 1,409 (AZ) + 91 (Moderna-mono) + 47 (Moderna-bivalent) + 83 (Unknown) = 2,564 = 0.5% of all reports (increase of 45 reports with fatal outcome in 8 weeks)
Over 405 of the above fatalities are of ‘unknown age’ = 15.8% of all fatalities, and >146 are of ‘unknown sex’ = 5.7% of all fatalities
CHILDREN & YOUNG PEOPLE SPECIAL REPORT
4,213,500 children (1st doses) – majority Pfizer (latest available dose total from November 2022)
Yellow Card Adverse Events Reported – Below combined 0-19 yrs – many categories retracted (^) due to fewer than five reports ‘in line with MHRA duty of confidentiality to patients and reporters’.
0-19-yr-old reports classified as SERIOUS* by MHRA = 71.4%
4,677 (Pfizer-mono) + >40 (Pfizer-bivalent) + 1,462 (AZ) + 518 (Moderna-mono) + >7 (Moderna-bivalent) + >36 (Unknown) = 6,740
0-19-yr-old reports classified as FATAL by MHRA
>11 (Pfizer-mono) + <5 (Pfizer-bivalent) + <5 (AZ) + <5 (Moderna-mono) + <5 (Moderna-bivalent) + <5 (Unknown brand) = greater than 17
20-29-yr-old reports classified as SERIOUS* by MHRA = 73.3%
20,033 (Pfizer-mono) + 123 (Pfizer-bivalent) + 14,563 (AZ) + 4,983 (Moderna-mono) + 136 (Moderna-bivalent) + < 5 (Novavax) + 99 (Unknown) = 39,937
20-29-yr-old reports classified as FATAL by MHRA
15 (Pfizer-mono) + <5 (Pfizer-bivalent) + 29 (AZ) + zero (Moderna-mono) + zero (Moderna-bivalent) + zero (Novavax) + zero (Unknown brand) = greater than 45
* MHRA definition of ‘serious’ – patient died, life threatening, hospitalisation, congenital abnormality, persistent or significant disability or capacity, deemed medically significant by MHRA medical dictionary or reporter
For full reports see here.
We will bring you a fuller up-to-date breakdown of the MHRA’s latest Yellow Card data release within the next week or so.
